HeartSciences (HSCS) Cost of Revenue (2021 - 2025)

HeartSciences (HSCS) has reported Cost of Revenue for 5 consecutive years, with $1008.0 the latest figure, recorded in Q4 2025.

• Quarterly Cost of Revenue changed N/A year-over-year to $1008.0 in Q4 2025, while the trailing twelve-month figure through Apr 2026 was $3648.0 (down 43.36% YoY) and the FY2026 annual result came in at $1768.0, down 5.96% from the prior year.
• Cost of Revenue rose to $1008.0 in Q4 2025 per HSCS's latest filing, from $760.0 in the prior quarter.
• Over the last five years, Cost of Revenue for HSCS reached as high as $5756.0 in Q3 2021 and fell as low as $760.0 in Q1 2023.
• A 5-year average of $2041.5 and a median of $1400.0 in 2022 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2022 — Cost of Revenue slumped 64.63% — and 2024, when it surged 500.13%.
• Year by year, Cost of Revenue stood at $5756.0 in 2021, then sank by 64.63% to $2036.0 in 2022, then fell by 25.34% to $1520.0 in 2023, then soared by 200.07% to $4561.0 in 2024, then plunged by 77.9% to $1008.0 in 2025.
• According to Business Quant data, Cost of Revenue over the past three periods registered $1008.0, $760.0, and $1880.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.